Business Description
F-star Therapeutics Inc
NAICS : 325412
SIC : 2834
Compare
Compare
Traded in other countries / regions
S4BA.Germany
•
FSTX.USA
Description
F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.12 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | -0.37 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0.31 | |||||
| Beneish M-Score | 13.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 17.82 | |||||
| 9-Day RSI | 17.81 | |||||
| 14-Day RSI | 21.95 | |||||
| 6-1 Month Momentum % | 89.01 | |||||
| 12-1 Month Momentum % | -8.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.23 | |||||
| Quick Ratio | 4.23 | |||||
| Cash Ratio | 3.46 | |||||
| Days Sales Outstanding | 49.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -156.95 | |||||
| Net Margin % | -178.51 | |||||
| ROE % | -41.65 | |||||
| ROA % | -32.11 | |||||
| ROIC % | -75.96 | |||||
| ROC (Joel Greenblatt) % | -854.95 | |||||
| ROCE % | -34.49 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.31 | |||||
| PB Ratio | 1.61 | |||||
| Price-to-Tangible-Book | 2.77 | |||||
| EV-to-EBIT | -2.07 | |||||
| EV-to-EBITDA | -2.15 | |||||
| EV-to-Forward-EBITDA | -1.13 | |||||
| EV-to-Revenue | 3.56 | |||||
| EV-to-Forward-Revenue | 20.17 | |||||
| EV-to-FCF | -2.15 | |||||
| Price-to-Net-Current-Asset-Value | 3.08 | |||||
| Price-to-Net-Cash | 4.61 | |||||
| Earnings Yield (Greenblatt) % | -48.34 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FSTX
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 20.801 | ||
| EPS (TTM) ($) | -1.5 | ||
| Beta | 0 | ||
| Volatility % | 123.88 | ||
| 14-Day RSI | 21.95 | ||
| 14-Day ATR ($) | 0.243735 | ||
| 20-Day SMA ($) | 5.9465 | ||
| 12-1 Month Momentum % | -8.33 | ||
| 52-Week Range ($) | 2.07 - 7.5847 | ||
| Shares Outstanding (Mil) | 21.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
F-star Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
F-star Therapeutics Inc Analysis
Share your researchHeadlines
See More
No news.